



Unique Pharmaceutical Laboratories

(A Div. of J.B.Chemicals & Pharmaceuticals Limited)

ACTIVE PHARMACEUTICAL INGREDIENTS

*** ATENOLOL USP**

(U.S.DMF NO. 024024)

Certificate of Suitability No. RO - CEP 2016 - 226 - Rev.00

*** CILNIDIPINE HCL**

(US DMF No. 27446)

*** DICLOFENAC ACID**

(U.S.DMF NO. 15366) (EU GMP approved Plant)

*** DICLOFENAC DIETHYLAMINE BP/EP**

(US DMF NO. 19020)

*** DICLOFENAC POTASSIUM BP/EP/USP**

(US FDA and EU GMP approved plant)(U.S.DMF No.15074)

*** DICLOFENAC SODIUM BP/EP/USP**

(U.S.DMF NO.12469)

(Spain DMF NO. DS-092 / 978) , (Canadian DMF No. 2005-055)

(Certificate of Suitability No. R1-CEP-1997-41-REVISION 05)

*** NIFEDIPINE BP/EP/USP**

(U.S.DMF No. 16730)

(Nifedipine USP Canadian DMF No. is : 2010-028)

(Certificate of Suitability NO.R1-CEP 2000-096-Rev.04)

"These products are not offered in countries where valid patents exist. However, final responsibility with respect to third party 's patent rights in a specific country lies exclusively with the user"

Contact Person:

B.K.Dhar

Unique Pharmaceutical Labs.

(A Division of J.B.Chemicals & Pharmaceuticals Ltd.)

Energy IT Park, Unit A, 8th Floor,

Appa Saheb Marathe Marg,

Prabhadevi,

Mumbai - 400 025.

New product launches in next 4-5 months.

- Furosemide
- Carbamazepine
- Glipizide
- Allopurinol

Phase 2: (4-6 months)

- Ezetimibe
- Bilastine
- Olmesartan